Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ischemia
Researchers from Dartmouth College detail findings in ischemia
August 14th, 2008
According to recent research from Lebanon, "The Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients With Critical Limb Ischemia (HGF-STAT trial) determined the effect of hepatocyte growth factor (HGF) plasmid on safety and limb tissue perfusion as measured by transcutaneous oxygen tension (TcPO2) in patients with critical limb ischemia (CLI). Randomized patients with rest pain or ischemic ulcers and TcPO2 < 40 mm Hg and/or toe pressure < 50 mm Hg received placebo or HGF-plasmid intramuscular injection as follows: 0.4 mg at days 0, 14, and 28 (low dose); 4.0 mg at days 0 and 28 (middle dose); or 4.0 mg at days...
Source: Gene Therapy Weekly (2008-08-14)
|
